"The only adverse event resulting surrounded by discontinuation of therapy within ≥ 3% of patients treated with Pletal 50 or 100 mg b.i.d. be headache, which occurred next to an incidence of 1.3%, 3.5%, and 0.3% in patients treated beside Pletal 50 mg b.i.d., 100 mg b.i.d, or placebo, respectively. Other frequent causes of discontinuation included palpitation and diarrhea, both 1.1% for cilostazol (all doses) versus 0.1% for placebo.
The most commonly reported adverse events, occurring within ≥ 2% of patients treated with Pletal 50 or 100 mg b.i.d., are shown contained by the table (below).
Other events seen beside an incidence of ≥ 2%, but occurring in the placebo group at tiniest as frequently as in the 100 mg b.i.d. group be: asthenia, hypertension, vomiting, leg cramps, hypesthesia, paresthesia, dyspnea, rash, hematuria, urinary tract infection, flu syndrome, angina pectoris, arthritis, and bronchitis. "
tablets and health guarantee correctness , is for informational purposes simply
Related Questions and Answers
No comments:
Post a Comment